German national case collection for familial pancreatic cancer (FaPaCa): ten years experience

被引:106
作者
Schneider, Ralph [1 ]
Slater, Emily P. [1 ]
Sina, Mercede [2 ]
Habbe, Nils [1 ]
Fendrich, Volker [1 ]
Matthaei, Elvira [1 ]
Langer, Peter [1 ]
Bartsch, Detlef K. [1 ]
机构
[1] Univ Marburg, Dept Visceral Thorac & Vasc Surg, D-35043 Marburg, Germany
[2] Univ Marburg, Inst Clin Genet, D-35043 Marburg, Germany
关键词
Familial pancreatic cancer; Genetic susceptibility; Screening; Hereditary tumor syndrome; HIGH-RISK INDIVIDUALS; GERMLINE MUTATIONS; BRCA2; MUTATIONS; ADENOCARCINOMA; PREVALENCE; NEOPLASIA;
D O I
10.1007/s10689-010-9414-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Familial pancreatic cancer (FPC) is a rare hereditary tumor syndrome. The 10-years experience of the national case collection for familial pancreatic cancer of Germany (FaPaCa) is reported. Since 1999 FaPaCa has collected families with at least two first-degree relatives with confirmed pancreatic cancer (PC), who did not fulfill the criteria of other hereditary tumor syndromes. Histopathological verification of tumor diagnoses, and genetic counseling were prerequisites for enrollment of families in FaPaCa. 94 of 452 evaluated families fulfilled the criteria for partaking in FaPaCa. PC represented the sole tumor entity in 38 (40%) families. In 56 families additional tumor types occurred, including breast cancer (n = 28), colon cancer (n = 20) and lung cancer (n = 11). In 70 (74%) families the pattern of inheritance was consistent with an autosomal dominant trait. Compared to the preceding generation, a younger age of onset was observed in the offspring of PC patients (median: 57 vs. 69 years), indicating anticipation. Mutation analyses of BRCA2, PALB2, CDKN2a, RNASEL, STK11, NOD2, CHEK2 and PALLD, revealed deleterious causative germline mutations of BRCA2 and PALB2 in 2 of 70 (3%) and 2 of 41 (4.9%) German FPC families, respectively. Prospective PC screening with EUS, MRI and MRCP detected precancerous lesions (IPMN, multifocal PanIN2/3) or carcinoma in 5.5% (4 of 72) to 12.5% (9 of 72) of individuals at risk, depending on histological verification. Appropriate inclusion of families at high risk for PC in registries, such as FaPaCa, provides a unique and excellent tool to gain clinical and genetic knowledge of FPC. Focused research projects can be conducted most efficiently, when data of different FPC registries are combined.
引用
收藏
页码:323 / 330
页数:8
相关论文
共 40 条
[1]   Genetic testing - Counseling, laboratory, and regulatory issues and the EUROPAC protocol for ethical research in multicenter studies of inherited pancreatic diseases [J].
Applebaum, SE ;
Kant, JA ;
Whitcomb, DC ;
Ellis, IH .
MEDICAL CLINICS OF NORTH AMERICA, 2000, 84 (03) :575-+
[2]   Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families [J].
Bartsch, D. K. ;
Langer, P. ;
Habbe, N. ;
Matthaei, E. ;
Chaloupka, B. ;
Sina, M. ;
Hahn, S. A. ;
Slater, E. P. .
CLINICAL GENETICS, 2010, 77 (04) :333-341
[3]   Low frequency of CHEK2 mutations in familial pancreatic cancer [J].
Bartsch, Detlef K. ;
Krysewski, Kristina ;
Sina-Frey, Mercedes ;
Fendrich, Volker ;
Rieder, Harald ;
Langer, Peter ;
Kress, Ralf ;
Schneider, Margarete ;
Hahn, Stephan A. ;
Slater, Emily P. .
FAMILIAL CANCER, 2006, 5 (04) :305-308
[4]   Update of familial pancreatic cancer in Germany [J].
Bartsch, DK ;
Sina-Frey, M ;
Ziegler, A ;
Hahn, SA ;
Przypadlo, E ;
Kress, R ;
Gerdes, B ;
Rieder, H .
PANCREATOLOGY, 2001, 1 (05) :510-516
[5]   RNASEL germline variants are associated with pancreatic cancer [J].
Bartsch, DK ;
Fendrich, V ;
Slater, EP ;
Sina-Frey, M ;
Rieder, H ;
Greenhalf, W ;
Chaloupka, B ;
Hahn, SA ;
Neoptolemos, JP ;
Kress, R .
INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (05) :718-722
[6]   CDKN2A germline mutations in familial pancreatic cancer [J].
Bartsch, DK ;
Sina-Frey, M ;
Lang, S ;
Wild, A ;
Gerdes, B ;
Barth, P ;
Kress, R ;
Grützmann, R ;
Colombo-Benkmann, M ;
Ziegler, A ;
Hahn, SA ;
Rothmund, M ;
Rieder, H .
ANNALS OF SURGERY, 2002, 236 (06) :730-737
[7]   Prevalence of familial pancreatic cancer in Germany [J].
Bartsch, DK ;
Kress, R ;
Sina-Frey, M ;
Grützmann, R ;
Gerdes, B ;
Pilarsky, C ;
Heise, JW ;
Schulte, KM ;
Colombo-Benkmann, M ;
Schleicher, C ;
Witzigmann, H ;
Pridöhl, O ;
Ghadimi, MB ;
Horstmann, O ;
von Bernstorff, W ;
Jochimsen, L ;
Schmidt, J ;
Eisold, S ;
Estévéz-Schwarz, L ;
Hahn, SA ;
Schulmann, K ;
Böck, W ;
Gress, TM ;
Zügel, N ;
Breitschaft, K ;
Prenzel, K ;
Messmann, H ;
Endlicher, E ;
Schneider, M ;
Ziegler, A ;
Schmiegel, W ;
Schäfer, H ;
Rothmund, M ;
Rieder, H .
INTERNATIONAL JOURNAL OF CANCER, 2004, 110 (06) :902-906
[8]   Screening for familial pancreatic cancer: is doing something better than doing nothing? [J].
Brand, Randall E. .
GUT, 2009, 58 (10) :1321-1322
[9]   Management strategies for patients with hereditary pancreatic cancer [J].
Brentnall T.A. .
Current Treatment Options in Oncology, 2005, 6 (5) :437-445
[10]   Screening for early pancreatic neoplasia in high-risk individuals: A prospective controlled study [J].
Canto, Marcia Irene ;
Goggins, Michael ;
Hruban, Ralph H. ;
Petersen, Gloria M. ;
Giardiello, Francis M. ;
Yeo, Charles ;
Fishman, Elliott K. ;
Brune, Kieran ;
Axilbund, Jennifer ;
Griffin, Constance ;
Ali, Syed ;
Richman, Jeffrey ;
Jagannath, Sanjay ;
Kantsevoy, Sergey V. ;
Kalloo, Anthony N. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (06) :766-781